198 related articles for article (PubMed ID: 22458700)
1. Expression of O⁶-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors.
Kanno H; Nishihara H; Oikawa M; Ozaki Y; Murata J; Sawamura Y; Kato M; Kubota K; Tanino M; Kimura T; Nagashima K; Itoh T; Tanaka S
Neuropathology; 2012 Dec; 32(6):647-53. PubMed ID: 22458700
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic study of pineal parenchymal tumors of intermediate differentiation.
Ito T; Kanno H; Sato K; Oikawa M; Ozaki Y; Nakamura H; Terasaka S; Kobayashi H; Houkin K; Hatanaka K; Murata J; Tanaka S
World Neurosurg; 2014; 81(5-6):783-9. PubMed ID: 23396072
[TBL] [Abstract][Full Text] [Related]
3. Pineal parenchymal tumors--utility of immunohistochemical markers in prognostication.
Arivazhagan A; Anandh B; Santosh V; Chandramouli BA
Clin Neuropathol; 2008; 27(5):325-33. PubMed ID: 18808064
[TBL] [Abstract][Full Text] [Related]
4. [Pathological and immunohistochemical study of pineal parenchymal tumors].
Fang J; Luo L; Li J; Sun S; Yuan Y
Zhonghua Bing Li Xue Za Zhi; 2002 Feb; 31(1):8-11. PubMed ID: 11955327
[TBL] [Abstract][Full Text] [Related]
5. Utility of Ki67 immunostaining in the grading of pineal parenchymal tumours: a multicentre study.
Fèvre-Montange M; Vasiljevic A; Frappaz D; Champier J; Szathmari A; Aubriot Lorton MH; Chapon F; Coulon A; Quintin Roué I; Delisle MB; Figarella-Branger D; Laquerrière A; Miquel C; Michiels JF; Péoch M; Polivka M; Fauchon F; Jouvet A
Neuropathol Appl Neurobiol; 2012 Feb; 38(1):87-94. PubMed ID: 21696422
[TBL] [Abstract][Full Text] [Related]
6. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
7. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
9. Pathology of pineal parenchymal tumors.
Sato K; Kubota T
Prog Neurol Surg; 2009; 23():12-25. PubMed ID: 19329858
[TBL] [Abstract][Full Text] [Related]
10. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
12. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characterization of pineal parenchymal tumors using novel monoclonal antibodies to the pineal body.
Yamane Y; Mena H; Nakazato Y
Neuropathology; 2002 Jun; 22(2):66-76. PubMed ID: 12075938
[TBL] [Abstract][Full Text] [Related]
14. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Wu PF; Kuo KT; Kuo LT; Lin YT; Lee WC; Lu YS; Yang CH; Wu RM; Tu YK; Tasi JC; Tseng HM; Tseng SH; Cheng AL; Lin CH
Lung Cancer; 2010 Jun; 68(3):484-90. PubMed ID: 19740564
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
16. [Pineal Parenchymal Tumor with Marked Cytologic Pleomorphism: Is there a Correlation with the Malignancy Grade?].
Ito T; Sato K; Ozaki Y; Asanome T; Nakamura H; Tanaka S; Kimura T; Kanno H
No Shinkei Geka; 2016 Jun; 44(6):481-7. PubMed ID: 27270146
[TBL] [Abstract][Full Text] [Related]
17. Expression of hydroxyindole-O-methyltransferase enzyme in the human central nervous system and in pineal parenchymal cell tumors.
Fukuda T; Akiyama N; Ikegami M; Takahashi H; Sasaki A; Oka H; Komori T; Tanaka Y; Nakazato Y; Akimoto J; Tanaka M; Okada Y; Saito S
J Neuropathol Exp Neurol; 2010 May; 69(5):498-510. PubMed ID: 20418777
[TBL] [Abstract][Full Text] [Related]
18. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Komori K; Yanagisawa R; Miyairi Y; Sakashita K; Shiohara M; Fujihara I; Morita D; Nakamura T; Ogiso Y; Sano K; Shirahata M; Fukuoka K; Ichimura K; Shigeta H
Pediatr Blood Cancer; 2016 Jan; 63(1):152-5. PubMed ID: 26305586
[TBL] [Abstract][Full Text] [Related]
20. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
